| Simultaneous measurement of more than six biosignals, including ECG, EEG, EMG, and oxygen saturation
| Built-in AI-based automatic sleep stage analysis and sleep apnea diagnostic algorithm
| “Resolving medical blind spots through patient- and user-centered innovation”

 

 

WisMedical CEO Sung Hoon Lee (Photo=WisMedical)

 

 

[BioTimes] Polysomnography (PSG) is a test conducted to diagnose and set treatment directions for various sleep disorders such as snoring, sleep apnea, and narcolepsy. While the procedure itself is non-invasive and safe, in reality, it comes with several limitations.

 

First, because multiple biosignals must be measured simultaneously, the process is complex and requires patients to visit specialized facilities. To accurately interpret information such as brainwaves, muscle movement, and breathing, trained professionals are also necessary. In addition, because the test is performed in an unfamiliar lab environment, patients often exhibit sleep patterns that differ from their normal state. Cost can also be a significant burden.

 

WisMedical is a company that develops flexible, advanced wearable biosensors and digital healthcare solutions. At present, it offers Tedream, a wireless wearable medical device for home-based sleep diagnostics, designed to replace complex polysomnography. The company name is short for Wearable Integrated Systems, embodying the mission “to create innovative medical devices that allow anyone to manage their health easily and conveniently through smart wearable devices.”

 

CEO Sung Hoon Lee explained, “The digital healthcare market is growing rapidly. As the era of using data not only in hospitals but also in homes and daily life is opening, demand for wearable devices and AI-based diagnostic and preventive solutions will continue to increase.”

We spoke with CEO Lee for more details.

 

 

WisMedical members (Photo=WisMedical)

 

 

◇ Replacing Polysomnography with Home-Based Wearable Sleep Diagnostics

 

CEO Lee earned his Ph.D. in Electrical and Computer Engineering at Georgia Tech and built extensive experience developing biosensors and healthcare systems. In clinical practice, he personally witnessed the inconvenience, cost burden, and accessibility issues of polysomnography experienced by both patients and medical staff. With the goal of changing the paradigm of sleep health, he founded WisMedical in 2022.

 

Currently, WisMedical’s key members include Co-CEO and CTO Professor Woon-Hong Yeo of Georgia Tech, CSO Dr. Seong Eun Kim, an expert in chemical and biomolecular engineering, CFO Yong-Seok Kwon, as well as specialists in medical device R&D, regulatory approval, clinical trials, and software development, both domestically and abroad.

 

The company’s flagship product, Tedream, is the world’s first ultra-thin, lightweight wearable sleep diagnostic patch. By attaching Tedream to the forehead, chest, and arm, users can easily and accurately conduct at home what was once only possible in hospitals. It simultaneously measures more than six biosignals—electrocardiogram (ECG), electroencephalogram (EEG), electromyogram (EMG), oxygen saturation (SpO₂), sleep posture, and respiratory sounds. It also comes with a built-in AI algorithm for automatic sleep stage analysis and sleep apnea diagnosis.

CEO Lee explained, “Tedream’s ultra-thin design and wireless communication technology reduce user discomfort while enabling accurate data collection. It controls motion artifacts and achieves accuracy comparable to polysomnography performed in hospitals.”

He continued, “Based on deep learning and machine learning, it provides accurate and automated sleep scoring and sleep disorder diagnosis. Sleep data are encrypted, securely uploaded, and stored in the cloud, while accessible medical services are being provided.”

 

 

Tedream (Photo=WisMedical)

 

 

◇ “Aiming to Be No.1 Global Sleep and Health Monitoring Solution”

 

WisMedical currently holds eight domestic and international patents and is preparing for GMP certification and medical device regulatory approval. It is collaborating with institutions such as Georgia Tech, Chungnam National University Hospital, and Seoul National University Bundang Hospital to develop innovative technologies in sleep, cardiovascular, and neurological health management. At present, pilot tests are underway at major hospitals, sleep clinics, insurance companies, and telemedicine providers both in Korea and abroad, and the company has accumulated data from hundreds of participants in collaboration with partners in the U.S., Korea, and Europe.

 

CEO Lee shared, “Thanks to support from various government programs, we have made progress in clinical trials, technology development, overseas expansion, network building, and early prototype development. Although we experienced trial and error in meeting medical device regulations, certification standards, and clinical protocol optimization in different countries, we quickly supplemented these issues by bringing in experts, consulting domestically and internationally, and repeating on-site testing.”

 

He emphasized, “Tedream possesses strengths such as its ultralight and ultrathin wearable patch form factor, multi-biosensor integration comparable to hospital-grade polysomnography, AI-based automatic diagnostic software, user-centered UX design, extensive global networks, clinical data, and intellectual property portfolio.”

 

With this technological edge, WisMedical has achieved strong results in several government programs and global startup competitions. Recently, it was named one of Fortune Korea’s Top 40 Innovative Companies. It was also selected for the 2024 Seoul Bio Hub–Draper Digital Healthcare Innovation Challenge, won the grand prize at the DMC Startup Competition, was chosen for Daewoong Pharmaceutical’s InnoBear program, and successfully exhibited at CES 2025.

 

 

(Photo=WisMedical home page capture)

 

 

WisMedical plans to raise a Pre-Series A investment round in the second half of this year, focusing on clinical trials and global medical device regulatory approvals. Next year, it aims to enter the U.S. and European markets in earnest, expand into new pipelines such as elderly care, pediatrics, and respiratory diseases, recruit talent, and broaden domestic and global strategic partnerships.

 

Ultimately, its goal is to become the world’s No.1 provider of sleep and health monitoring solutions.

CEO Lee stated, “Our role model is Medtronic, which has long maintained a pioneering position in the global medical device market. Medtronic never stops making strategic investments aligned with market trends—not only in future-oriented areas such as robotic surgery, AI, and personalized medicine, but also in achieving innovation in diabetes care and solid growth in the cardiovascular field.”

 

He concluded, “WisMedical’s mission is ‘Easy and accurate health diagnostics for all, for a better life.’ Through patient- and user-centered innovation, we aim to resolve medical blind spots and create a future where everyone can manage their health in daily life.”

 

[BioTimes=Reporter SeoKyung Shin] ssk@biotimes.co.kr

 

 

 

Seokyung Shin Reporter 

Accepted 2025.08.26 17:25

https://www.biotimes.co.kr/news/articleView.html?idxno=23604